News

OpenAI's No. 2 Exit and Chronic Illness at Work

Fidji Simo, OpenAI's CEO of Applications and the company's most senior executive below Sam Altman, announced July 9 that she is stepping down from the full-time role and transitioning to a part-time advisory position. The departure follows a medical leave she took in April after disclosing a relapse of a chronic neuroimmune condition — leave that, as she told staff in a memo, proved longer and harder than expected.

Simo joined OpenAI in May 2025 to fill a newly created role that consolidated the company's business and product operations, reporting directly to Altman. Before that, she spent more than a decade at Meta, where she ran the Facebook app, and later served as CEO of Instacart, leading that company through its 2023 IPO. Altman responded to the news publicly, writing that he was "really sad about this" and grateful for her work and friendship.

Context

The timing is significant. OpenAI is preparing for a potential IPO, and Simo — with her direct experience guiding Instacart to public markets — had been widely seen as a key figure in that process. With her stepping back, OpenAI faces a real leadership gap at a moment when operational stability matters most to investors.

TechCrunch's reporting notes that Greg Brockman, OpenAI's president, was overseeing product strategy during Simo's absence. On the succession question, the outlet notes it would not be surprising to see Denise Dresser — OpenAI's Chief Revenue Officer and a former Slack CEO and Salesforce executive — move into a broader role. Finimize's coverage also flags the IPO groundwork as the backdrop that makes the leadership gap particularly consequential.

What this means for job seekers

Simo's story cuts through the usual corporate silence around health and work. Rather than stepping back quietly or waiting until her condition forced a clean break, she disclosed a neuroimmune relapse publicly and then negotiated a reduced-scope advisory arrangement instead of a full exit. That sequence — disclose, adapt, remain involved — is worth paying attention to.

For anyone navigating a chronic condition alongside a career, the lesson is practical: an advisory or fractional role is a legitimate off-ramp, not a consolation prize. More companies, especially in tech, are structuring these arrangements formally. The challenge is knowing how to ask for one. In reviewing the career landscape, we find that the strongest cases for a scope reduction come when a professional can demonstrate what they uniquely contribute — deep institutional knowledge, a specific network, strategic relationships — and frame the reduced role around preserving exactly that value.

The disclosure piece is evolving too. Simo was a C-suite executive with massive public visibility, and she chose transparency over silence. That sets a different norm than the one most employees experience — where the fear of being quietly managed out keeps health struggles private. Disclosure still carries real risk at many organizations, and context matters enormously. But the growing number of senior leaders who speak openly about neuroimmune and other chronic conditions does shift what feels possible.

For job seekers in the hiring pool right now: OpenAI's No. 2 seat is effectively open. The role Simo held — bridging product and business operations at one of the most closely watched companies in tech — represents the kind of general-manager-plus-operator profile that will be competed for fiercely. If your background includes revenue operations, product leadership, or taking a company through a capital event, this signals where demand is moving at the top of the AI market.